Journal · Updated 2026-08-11
Oak Longevity Review 2026: The Quiet $133 That Almost Leads
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
One thirty-three a month, month-to-month, compounded semaglutide — four dollars off bmiMD's floor, no commitment required, which makes Oak Longevity the quiet second name on the no-commitment semaglutide podium. The rest of the row is thinner than the price: a small operator, no tirzepatide in our records, and a pharmacy partner not publicly itemized — which converts the review into the standard extraction with higher-than-usual stakes, because near-floor prices from small operators are exactly where verification earns its keep.
The small-operator calculus, and verdict
Small isn't a strike — some of this market's best behavior lives at operators too small for growth-marketing gymnastics — but it concentrates the diligence: the pharmacy name and fifteen-minute verification matter more when the operator's own paper trail is short; dose-flatness and exit terms belong in writing; and month-to-month billing (confirmed, not assumed) is the structure that keeps the downside to one month's exposure. Cleared, Oak is a legitimate floor-adjacent pick with the market's simplest risk shape. The placement notes: four dollars monthly to bmiMD buys, at bmiMD, a published four-rung ladder down to ninety-nine and an advertised-named-pharmacy claim — so Oak's case is strongest for the buyer who specifically prefers a smaller shop and has done the fifteen minutes. Semaglutide only; tirzepatide shoppers pass by.
Questions people ask
How much is Oak Longevity?
$133/month, month-to-month, for compounded semaglutide — $4 off the tracked floor, no commitment. No tirzepatide in our records.
Is Oak Longevity trustworthy?
Our records show a clean price and a thin public trail — small operator, pharmacy not publicly itemized — which makes the standard verification load-bearing: extract the pharmacy name, run the license lookups and COA request, and confirm month-to-month billing and exit terms in writing before the first charge.
Oak vs bmiMD for semaglutide?
$133 vs $129 month-to-month — near a tie. bmiMD adds a published ladder to $99 committed and a named-pharmacy claim; Oak offers the smaller-shop alternative at four dollars more. Verification quality, not price, should decide it.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.